Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092855 | 0.92 | KDR (0.44) | UGCGMAPTSMN1; SMN2THRBKDR | |
| SCHEMBL15000662 | 0.91 | CRACR2A (0.41) | UGCGMAPTSMN1; SMN2IDO1NPC1 | |
| SCHEMBL27717122 | 0.84 | KDR (0.52) | MAPTSMN1; SMN2THRBKDRMET | |
| SCHEMBL2091845 | 0.84 | NPC1 (0.44) | KDRNPC1RAB9ACRACR2ATP53 | |
| SCHEMBL2095265 | 0.84 | NPC1 (0.44) | MAPTSMN1; SMN2KDRNPC1RAB9A | |
| SCHEMBL13001539 | 0.84 | CRACR2A (0.41) | UGCGMAPTSMN1; SMN2IDO1NPC1 | |
| SCHEMBL15000646 | 0.84 | CRACR2A (0.41) | UGCGMAPTSMN1; SMN2IDO1NPC1 | |
| SCHEMBL2095424 | 0.83 | MAPT (0.44) | UGCGMAPTSMN1; SMN2IDO1NPC1 | |
| SCHEMBL2092336 | 0.82 | CRACR2A (0.42) | UGCGMAPTSMN1; SMN2IDO1NPC1 | |
| SCHEMBL2091639 | 0.81 | ALDH1A1 (0.42) | UGCGMAPTSMN1; SMN2NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | NLRP3, CXCR1, CXCR2 | UGCG 2989/4885MAPT 1930/4885SMN1; SMN2 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.